Register
Login:
Share:
Email Facebook Twitter




SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.225Bid: 0.22Ask: 0.23Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.01Spread as %: 4.55%Open: 0.225High: 0.225Low: 0.21Yesterday’s Close: 0.225


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


Utahsaints
Posts: 329
Off Topic
Opinion:No Opinion
Price:0.58
Motives
1 Oct '14
I hold 1.7m

It's the market who decides price( meant to anyway) all I'm saying is the expectation of really good news means that a no news RNS makes the market believe that nothing really positive will happen any day soon and pushes out the pay day. Rightly or wrongly there is lots of negativity around sareum
 
Fredd1eboy
Posts: 916
Premium Chat Member
Answer
Opinion:Strong Buy
Price:0.58
fao. kazirira
1 Oct '14
Good call. Common sense will prevail. I've just topped up this morning at a good price. Best wishes. Freddie
kazimira
Posts: 137
Off Topic
Opinion:No Opinion
Price:0.58
Utahsaints
1 Oct '14
Taking a somewhat longer-term view than the first hour's trading, note what the Journal of Immunology says: "the administration of SAR-20347 led to a striking decrease in disease pathology". For a scientist, a phrase such as "striking decrease" is pretty exciting language!
Latino
Posts: 1,680
Off Topic
Opinion:No Opinion
Price:0.60
Utah
1 Oct '14
Why are you predicting drop? when all they have done is announce what's has been printed in the journals. I question your motives here.
Utahsaints
Posts: 329
Off Topic
Opinion:No Opinion
Price:0.58
Ok
1 Oct '14
Fair dos

Share price down today I can see this 10-15% down end of day
PHILBORO
Posts: 704
Observation
Opinion:Strong Buy
Price:0.65
R Oh!
1 Oct '14
Just saying mate, not a lot in the scheme of things but you can't say there hasn't been buying over the last week or so
Utahsaints
Posts: 329
Off Topic
Opinion:No Opinion
Price:0.60
Oh!
1 Oct '14
5 million big deal!
PHILBORO
Posts: 704
Observation
Opinion:Strong Buy
Price:0.60
5 million
1 Oct '14
buys this morning already suggests your talking out of a different hole
Utahsaints
Posts: 329
Off Topic
Opinion:No Opinion
Price:0.60
Buying
1 Oct '14
No one interested in buying this share TM needs to think what he is doing why RNS?any ideas anyone?
kazimira
Posts: 137
Off Topic
Opinion:No Opinion
Price:0.60
Journal of Immunology Abstract
1 Oct '14
For the medically minded:

Abstract
Psoriasis is a chronic autoimmune disease affecting the skin and characterized by aberrant keratinocyte proliferation and function. Immune cells infiltrate the skin and release proinflammatory cytokines that play important roles in psoriasis. The Th17 network, including IL-23 and IL-22, has recently emerged as a critical component in the pathogenesis of psoriasis. IL-22 and IL-23 signaling is dependent on the JAK family of protein tyrosine kinases, making JAK inhibition an appealing strategy for the treatment of psoriasis. In this study, we report the activity of SAR-20347, a small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members. In cellular assays, SAR-20347 dose dependently (1 nM–10 μM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-23, IL-22, and IFN-α receptors. In vivo, TYK2 mutant mice or treatment of wild-type mice with SAR-20347 significantly reduced IL-12–induced IFN-γ production and IL-22–dependent serum amyloid A to similar extents, indicating that, in these models, SAR-20347 is probably acting through inhibition of TYK2. In an imiquimod-induced psoriasis model, the administration of SAR-20347 led to a striking decrease in disease pathology, including reduced activation of keratinocytes and proinflammatory cytokine levels compared with both TYK2 mutant mice and wild-type controls. Taken together, these data indicate that targeting both JAK1- and TYK2-mediated cytokine signaling is more effective than TYK2 inhibition alone in reducing psoriasis pathogenesis.





Sign up for Live Prices


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.